Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

Detalles Bibliográficos
Autores principales: Nakai, Ritsuko, Fukuhara, Suguru, Maeshima, Akiko Miyagi, Kim, Sung‐Won, Ito, Yuta, Hatta, Shunsuke, Suzuki, Tomotaka, Yuda, Sayako, Makita, Shinichi, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935642/
https://www.ncbi.nlm.nih.gov/pubmed/31893088
http://dx.doi.org/10.1002/ccr3.2543
Descripción
Sumario:This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

Ejemplares similares